Trial Profile
A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Dec 2011
Price :
$35
*
At a glance
- Drugs Benzalkonium chloride (Primary) ; Gatifloxacin; Moxifloxacin
- Indications Bacterial infections; Conjunctivitis
- Focus Pharmacodynamics
- Sponsors Allergan
- 16 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Apr 2009 New trial record